Patient Support Line 1-800-282-7630, Monday – Friday: 9 AM – 5 PM ET
Proven Survival Results in HR+, HER2- mBC
KISQALI is approved for both pre- and postmenopausal women or in men with HR+, HER2- metastatic breast cancer (mBC). KISQALI has extended lives in multiple clinical trials when taken in combination with a nonsteroidal aromatase inhibitor or fulvestrant. Watch the video below to see why women are asking for KISQALI by name.